Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RD06-04 CAR-T in active autoimmune diseases
NCT06549296Phase 1Suspended
- Sponsor
- Bioheng Therapeutics
- Start
- Sep 2024
- Primary completion
- Aug 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RD06-04 in systemic lupus erythematosus (SLE), systemic sclerosis (SSc), Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) and 2 more, sponsored by Bioheng Therapeutics. Primary endpoints: Treatment-Emergent Adverse Events at 2 years, Serious Adverse Events at 2 years and 1 more. Started Sep 2024; status: suspended.
02
Drugs
RD06-04
03
Conditions
systemic lupus erythematosus (SLE)systemic sclerosis (SSc)Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)idiopathic inflammatory myopathies (IIM)primary Sjögren's syndrome
Beyond the preview
Go deeper on NCT06549296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06549296.